Ketorolac in Second Trimester: Not Recommended
Ketorolac should be avoided during the second trimester of pregnancy, as it carries specific fetal risks and is not among the preferred NSAIDs for this period when short-term use is absolutely necessary.
Evidence-Based Reasoning
The most recent 2025 EULAR guidelines 1 provide clear direction on NSAID use during pregnancy, though they do not specifically endorse ketorolac. The guidelines state that when NSAIDs are needed in the second trimester, nonselective NSAIDs with short half-lives (specifically ibuprofen) are favored in the lowest effective dose for 7-10 days maximum 1. Ketorolac is notably absent from this recommendation.
Why Ketorolac is Problematic
The FDA labeling classifies ketorolac as Pregnancy Category C 2. While animal studies at therapeutic doses did not show teratogenicity, the label explicitly warns that "use during pregnancy (particularly late pregnancy) should be avoided" due to effects on the fetal cardiovascular system 2.
Most concerning, a 2025 population study of over 1 million children found that ketorolac exposure specifically in the first trimester was associated with increased childhood chronic kidney disease risk (weighted HR 1.28,95% CI 1.01-1.62) 3. While this study focused on first trimester exposure, it raises significant safety concerns about ketorolac's fetal nephrotoxicity potential that extends beyond what is seen with preferred NSAIDs like ibuprofen.
Clinical Algorithm for Second Trimester Pain Management
If NSAID use is being considered in the second trimester:
- First choice: Ibuprofen at the lowest effective dose 1
- Duration: Limit to 7-10 days maximum 1
- Timing: Must discontinue by gestational week 28 (end of second trimester) 1
- Monitoring: Not specifically required for short-term use, but avoid if fertility concerns exist 1
Ketorolac should not be selected when ibuprofen or other preferred short-acting NSAIDs are available.
Key Safety Considerations
Fetal Risks with All NSAIDs in Second Trimester
- Dose-dependent effects on prostaglandin inhibition 1
- Potential for oligohydramnios with prolonged use 1
- Risk of premature ductus arteriosus constriction increases as pregnancy advances 1
- Ketorolac specifically shows renal toxicity signals 3
Common Pitfall to Avoid
Do not assume all NSAIDs are equivalent in pregnancy. The 2025 EULAR guidelines specifically favor ibuprofen based on the most reassuring safety data 1. A 2019 systematic review confirmed that short-term second trimester NSAID use appears reasonably safe, but this evidence is predominantly based on ibuprofen and indomethacin for tocolysis—not ketorolac for analgesia 4.
Alternative Approach
If ketorolac is being considered for acute pain requiring parenteral administration, consider whether the clinical situation truly requires an NSAID over acetaminophen or whether oral ibuprofen would suffice. The FDA label notes ketorolac "should be used during pregnancy only if the potential benefit justifies the potential risk" 2—a high bar that is rarely met in the second trimester when safer alternatives exist.
Bottom line: Choose ibuprofen if an NSAID is absolutely necessary in the second trimester, limit to 7-10 days, and discontinue by week 28.